Toll-like receptors: New players in myocardial ischemia/reperfusion injury

Antioxidants and Redox Signaling

Volumn 15, Issue 7, 2011, Pages 1875-1893

  Ha, Tuanzhu ^a   Liu, Li ^b   Kelley, Jim ^a   Kao, Race ^a   Williams, David ^a   Li, Chuanfu ^a  

^a East Tennessee State University   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CD36 ANTIGEN; ERITORAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; LIGAND; LIPOPEPTIDE; LIPOPROTEIN PAM3CSK4; MICRORNA; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDOGLYCAN; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMID DNA; PROTEIN KINASE B; SCAVENGER RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165; WORTMANNIN;

ANGINA PECTORIS; ANGIOGENESIS; ENZYME ACTIVATION; GENETIC TRANSFECTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTIGENS, BACTERIAL; GENE SILENCING; GENE THERAPY; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERFERON REGULATORY FACTOR-3; MICRORNAS; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TOLL-LIKE RECEPTORS;

EID: 80051661231     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3723     Document Type: Review

References (195)

1. Abarbanell AM, Wang Y, Herrmann JL, Weil BR, Poynter JA, Manukyan MC, and Meldrum DR. Toll-like receptor 2 mediates mesenchymal stem cell associated myocardial recovery and VDGF production following acute ischemia/reperfusion injury. Am J Physiol Heart Circ Physiol 298: H1529-H1536, 2010.
2. Aderem A and Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 406: 782-787, 2000.
3. Akira S and Takeda K. Toll-like receptor signalling. Nat Rev 4: 499-511, 2004. (Pubitemid 38931765)
4. Akira S, Takeda K, and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680, 2001. (Pubitemid 32747155)
5. Akira S, Uematsu S, and Takeuchi O. Pathogen recognition and innate immunity. Cell 124: 783-801, 2006. (Pubitemid 43261452)
6. Amiel E, Alonso A, Uematsu S, Akira S, Poynter ME, and Berwin B. Toll-like receptor regulation of scavenger receptor-A-mediated phagocytosis. J Leukocyte Biol 85: 595-605, 2009.
7. Anderson KV. Toll signaling pathways in the innate immune response. Curr Opin Immunol 12: 13-19, 2000. (Pubitemid 30093445)
8. Anderson KV, Bokla L, and Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 42: 791-789, 1985.
9. Anderson KV, Jurgens G, and Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 42: 779-789, 1985. (Pubitemid 16083719)
10. Ao L, Zou N, Cleveland JC Jr., Fullerton DA, and Meng X. Myocardial TLR4 is a determinant of neutrophil infiltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70. Am J Physiol Heart Circ Physiol 297: H21-H28, 2009.
11. Arbibe L, Mira J-P, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, and Knaus UG. Toll-like receptor 2-mediated NF-kB activation requires a RAC Idependent pathway. Nat Immunol 1: 533-540, 2000.
12. Areschoug T and Gordon S. Pattern recognition receptors and their role in innate immunity: focus on microbial protein ligands. Contrib Microbiol 15: 45-60, 2008.
13. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, and de Kleijn DP. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 121: 80-90, 2010.
14. Arumugam TV, Okun E, Tang S-C, Thundyil J, Taylor SM, and Woodruff TM. Toll-Like Receptors in Ischemia-Reperfusion Injury. Shock 32: 4-16, 2009.
15. Asehnoune K, Strassheim D, Mitra S, Kim JY, and Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 172: 2522-2529, 2004. (Pubitemid 38182403)
16. Baeuerle PA and Baltimore D. NF-kB: ten years after. Cell 87: 13-20, 1996.
17. Barry WH. Mechanisms of immune-mediated myocyte injury. Circulation 89: 2421-2432, 1994. (Pubitemid 24142825)
18. Baumgarten G, Kim S-C, Stapel H, Vervolgyi V, Bittig A, Hoeft A, Meyer R, Grohe C, and Kneufermann P. Myocardial injury modulates the innate immune system and changes myocardial sensitivity. Basic Res Cardiol 101: 427-435, 2006. (Pubitemid 44275876)
19. Binck BW, Tsen MF, Islas M, White DJ, Schultz RA, Willis MS, et al. Bone marrow-derived cells contribute to contractile dysfunction in endotoxic shock. Am J Physiol Heart Circ Physiol 288: 577-583, 2005.
20. Blasius AL and Beutler B. Intracellular toll-like receptors. Immunity 32: 305-315, 2010.
21. Boyd JH, Mathur S, Wang Y, Bateman RM, and Walley KR. Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72: 384-393, 2006. (Pubitemid 44665856)
22. Bozkurt B, Jribb SB, Clubb FJ, Michael LH, Didenko VV, Hornsby PJ, Yukihiro S, Oral H, Spinale FG, and Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97: 1382-1391, 1998. (Pubitemid 28182677)
23. Brightbill HD and Modlin RL. Toll-like receptors: molecular mechanisms of the mammalian immune response. Immunology 101: 1-10, 2000.
24. Brown JM, Grosso MA, Terada LS, and Whitman GJR. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA 86: 2516-2520, 1989. (Pubitemid 19102539)
25. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, and Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97: 1375-1381, 1998. (Pubitemid 28182676)
26. Cantley LC. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002. (Pubitemid 34579158)
27. Caso J, Pradillo J, Hurtado O, Lorenzo P, Moro M, and Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 115: 1599-1608, 2007. (Pubitemid 46648645)
28. Cha J, Wang Z, Ao L, Zou N, Dinarello CA, Banerjee A, Fullerton DA, and Meng X. Cytokines link Toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. Ann Thorac Surg 85: 1678-1685, 2008. (Pubitemid 351608179)
29. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol 296: H12, 2009.
30. Chen X-M, Splinter PL, O'Hara SP, and LaRusso NF. A cellular micro-RNA, let-7i, regulates toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem 282: 28929-28938, 2007. (Pubitemid 47610421)
31. Cheng Y, Liu X, Zhang S, Lin Y, Yang J, and Zhang C. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 47: 5-14, 2009.
32. Cho ML, Ju JH, Kim HR, Oh HJ, Kang CM, Jhun JY, Lii SY, Park MK, Min JK, Park SH, Lee SH, and Kim HY. Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts. Immunol Lett 108: 121-128, 2007.
33. Cho S, Park E-M, Febbraio M, Anrather J, Park L, Racchumi G, Silverstein RL, and Iadecola C. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci 25: 2504-2512, 2005. (Pubitemid 40365160)
34. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, and Verrier ED. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 128: 170-179, 2004. (Pubitemid 38969797)
35. Chuang T-H and Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 1518: 157-161, 2001. (Pubitemid 32232289)
36. Dong JW, Vallejo JG, Tzeng HP, Thomas JA, and Mann DL. Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol 298: H1079-H1087, 2010.
37. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, Wang D, Kralll TJ, Delphin ES, and Zhang C. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 284: 29514-29525, 2009.
38. Doyle SL and O'Neill LAJ. Toll-like receptors: from the discovery of NFkB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 72: 1102-1113, 2006. (Pubitemid 44468394)
39. Du X, Poltorak A, Wei Y, and Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw 11: 362-371, 2000. (Pubitemid 32268893)
40. Dutka DP, Elborn JS, Delamere F, Shale DJ, and Morris GK. Tumor necrosis factor alpha in severe congestive cardiac failure. Br Heart J 70: 141-143, 1993. (Pubitemid 23248028)
41. Fallach R, Shainberg A, Avlas O, Fainblut M, Chepurko Y, Porat E, and Hochhauser E. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J Mol Cell Cardiol 48: 1236-1244, 2010.
42. Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal JF, Thuillez C, and Richard V. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 27: 1064-1071, 2007. (Pubitemid 46641958)
43. Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H, Scherrer-Crosbie M, Schmidt U, and Chao W. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 295: H1311-H1318, 2008.
44. Fishtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Roxe T, Muller-Ardogan M, Bonauer A, Zeiher AM, and Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res 107: 677-684, 2010.
45. Flohe L, Brigelius-Flohe R, Saliou C, Traber MG, and Packer L. Redox regulation of NF-kB activation. Free Radic Biol Med 22: 1115-1126, 1997.
46. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal 8: 1907-1939, 2006. (Pubitemid 46504897)
47. Frantz S, Bauersachs J, and Kelly RA. Innate immunity and the heart. Curr Pharm Des 11: 1279-1290, 2005. (Pubitemid 40458273)
48. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medshitov R, Lee RT, and Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104: 271-280, 1999.
49. Fruman DA and Cantley LC. Phosphoinositide 3-kinase in immunological systems. Semin Immunol 14: 7-18, 2002. (Pubitemid 34250704)
50. Fuh E and Brinton TJ. Bone marrow stem cells for the treatment of ischemic heart disease: a clinical trial review. J Cardiovasc Transl Res 2: 202-218, 2009.
51. Fujio Y, Nguyen T, Wencker D, Kitsis RN, and Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101: 660-667, 2000. (Pubitemid 30094738)
52. Fukao T and Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol 24: 358-363, 2003. (Pubitemid 36830961)
53. Fukao T, Tanabe M, Terauchi Y, Ota T, Matsuda S, Asano T, Kadowak T, Takeuchi T, and Koyasu S. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol 3: 875-881, 2002.
54. Gill R, Tsung A, and Billiar T. Linking oxidative stress to inflammation: toll-like receptors. Free Radic Biol Med 48: 1121-1132, 2010.
55. Goldstein JL, Ho YK, Basu SK, and Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76: 333-337, 1979. (Pubitemid 9110191)
56. Goodridge HS and Underhill DM. Fungal recognition by TLR2 and Dectin-1. Hand Exp Pharmacol 183: 87-109, 2008.
57. Greaves DR and Gordon S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J Lipid Res 50 (Supplement): S282-S286, 2009.
58. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N, and Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 42: 1339-1347, 2003. (Pubitemid 37267270)
59. Grote K, Schuett H, Salguero G, Grothusen C, Jagielska J, Drexler H, Muhlradt PF, and Schieffer B. Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration. Blood 115: 2543-2552, 2010.
60. Guha M and Mackman N. The PI3K-Akt pathway limits LPS activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 277: 32124-32132, 2002. (Pubitemid 34969025)
61. Ha T, Hu Y, Liu L, Lu C, McMullen JR, Shioi T, Isumo S, Kelley J, Kao RL, Williams DL, Gao X, and Li C. TLR2 ligands induce cardioprotection against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc Res 87: 694-703, 2010.
62. Ha T, Hua F, Liu X, Ma J, McMullen JR, Shioi T, Izumo S, Kelley J, Gao X, Browder W, Williams DL, Kao RL, and Li C. Lipopolysaccharide-induced myocardial protection against ischemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res 78: 546-553, 2008. (Pubitemid 351769766)
63. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, Browder IW, Kao RL, and Li C. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 68: 224-234, 2005. (Pubitemid 41428419)
64. Ha T, Lu C, Liu L, Hua F, Hu Y, Kelley J, Singh K, Kao RL, Kalbfleisch J, Williams DL, Gao X, and Li C. TLR2 ligands attenuate cardiac dysfunction in polymicrobial sepsis via a phosphoinositide-3-kinase dependent mechanism. Am J Physiol Heart Circ Physiol 298: H984-H991, 2010.
65. Haudek SB, Spencer E, Bryant DD, White DJ, Maass D, Horton JW, Chen ZJ, and Giroir BP. Overexpression of cardiac I-kBa prevents endotoxin-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 280: H962-H968, 2001.
66. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, Vanninen E, Mussalo H, Kauppila E, Simula S, Narvanen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, and Yla-Herttuala S. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107: 2677-2683, 2003. (Pubitemid 36667240)
67. Hennessy EJ, Parker AE, and O'Neill LAJ. Targeting Toll-like receptors: emerging therapeutics? Nat Rev 9: 293-307, 2010.
68. Herskowitz A, Choi S, Ansari AA, and Wesselingh S. Cytokine mRNA expression in postischemic/reperfusion myocardium. Am J Pathol 146: 419-428, 1995.
69. Hollifield M, Bou Ghanem E, de Villiers WJ, and Garvy BA. Scavenger receptor A dampens induction of inflammation in response to the fungal pathogen Pneumocystis carinii. Infect Immun 75: 3999-4005, 2007. (Pubitemid 47206298)
70. Hua F, Ha T, Ma J, Gao X, Kelley J, Williams DL, Browder IW, Kao RL, and Li C. Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem Biophys Res Comm 338: 1118-1125, 2005. (Pubitemid 41597753)
71. Hua F, Ha T, Ma J, Li Y, Kelley J, Gao X, Browder IW, Kao RL, Williams DL, and Li C. Protection against myocardial ischemia/reperfusion injury in TLR4 deficient mice is mediated through a phosphoinositide 3-kinase dependent mechanism. J Immunol 178: 7317-7324, 2007. (Pubitemid 46847459)
72. Hua F, Ma J, Ha T, Kelley J, Williams DL, Kao RL, Kalbfleisch JH, Browder IW, and Li C. Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J Neuroimmunol 199: 75-82, 2008.
73. Hua F, Ma J, Ha T, Kelley JL, Kao RL, Schweitzer JB, Kalbfleisch JH, Williams DL, and Li C. Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice. Brain Res 1262: 100-108, 2009.
74. Hua F, Ma J, Ha T, Xia Y, Kelley J, Williams DL, Kao RL, Browder IW, Schweitzer JB, Kalbfleisch JH, and Li C. Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. J Neuroimmunol 190: 101-111, 2007. (Pubitemid 47625617)
75. Jagavelu K, Routray C, Shergill U, O'Hara SP, Faubion W, and Shah VH. Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology 52: 590-601, 2010.
76. Janssen-Heininger YM, Poynter ME, and Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kB. Free Radic Biol Med 28: 1317-1327, 2000. (Pubitemid 30621476)
77. Jefferies CA and Fitzgerald KA. Interferon gene regulation: not all roads lead to Tolls. Science 11: 403-411, 2005.
78. Jones WK, Brown M, Ren X, He S, and McGuinness M. NFkB as an integrator of diverse signaling pathways. Cardiovasc Toxicol 3: 229-253, 2003.
79. Jope RS and Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 96-102, 2004.
80. Kanzler H, Barrat FJ, Hessel EM, and Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559, 2007. (Pubitemid 46830615)
81. Kao RL, Browder W, and Li C. Cellular cardiomyoplasty: what have we learned? Asian Cardiovasc Thorac Ann 17: 89-101, 2009.
82. Kapadia S, Dibbs Z, Kurrelmeyer K, Kalra D, Seta Y, Wang F, Buzkurt B, Oral H, Sivasubramanian N, and Mann DL. The role of cytokines in the failing human heart. Cardiol Clin 16: 645-656, 1998. (Pubitemid 28509448)
83. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W, Botker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyongyosi M, Sylven C, and Euroinject One Group. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 45: 982-988, 2005. (Pubitemid 40432426)
84. Katsargyris A, Klonaris C, Bastounis E, and Theocharis S. Toll-like receptor modulation: a novel therapeutic strategy in cardiovascular disease? Expert Opin Ther Targets 12: 1329-1346, 2008.
85. Katz SD, Rao R, and Berman JW. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Circulation 90: 12-16, 1994.
86. Kawai T and Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384, 2010.
87. Kelly RA and Smith TW. Cytokines and cardiac contractile function. Circulation 95: 778-781, 1997. (Pubitemid 27091510)
88. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, and Willeit J. Chronic infections and the risk of carotid atherosclerosis. Circulation 103: 1064-1070, 2001.
89. Kim E, Tolhurst AT, Qin LY, Chen X-Y, Febbraio M, and Cho S. CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia- induced exacerbation in ischemic brain injury. J Neurosci 28: 4661-4670, 2008.
90. Kim SC, Ghanem A, Stapel H, Tiemann K, Knuefermann P, Hoeft A, Meyer R, Grohe C, Knowlton AA, and Baumgarten G. Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol 7: 1-10, 2007.
91. King CG, Kobayashi T, Cejas PJ, Kim T, Yoon K, Kim GK, Chiffoleau E, Hickman SP, Walsh PT, Turka LA, and Choi Y. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 12: 1088-1092, 2006. (Pubitemid 44353391)
92. Kubota T, McTiernan CF, Frye CS, Demetris AJ, and Feldman AM. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Card Fail 3: 117-124, 1997. (Pubitemid 127675015)
93. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, and Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81: 627-635, 1997. (Pubitemid 27432751)
94. Kukielka GL, Smith CW, LaRosa GJ, Manning AM, Mendoza LH, Daly TJ, Hughes BJ, Youker KA, Hawkins HK, Michael LH, and Entman ML. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 95: 89-103, 1995.
95. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael L, and Entman ML. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation 92: 1866-1875, 1995.
96. Kunz A, Abe T, Hochrainer K, Shimamura M, Anrather J, Racchumi G, Zhou P, and Iadecola C. Nuclear factor-kB activation and postischemic inflammation are suppressed in CD36-null mice after middle cerebral artery occlusion. J Neurosci 28: 1649-1658, 2008. (Pubitemid 351287045)
97. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, and Vogel SN. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol 85: 966-977, 2009.
98. Lange LG and Schreiner GF. Immune mechanisms of cardiac disease. N Engl J Med 330: 1129-1135, 1994. (Pubitemid 24118272)
99. Lavu M, Gundewar S, and Lefer DJ. Gene therapy for ischemic heart disease. J Mol Cell Cardiol 2010 [Epub ahead of print]; DOI: 10.1016/j.yjmcc.2010.06.007.
100. Lefer A and Rovetto M. Influence of a myocardial depressant factor on physiologic properties of cardiac muscle. Proc Soc Exp Biol 134: 269-273, 1970.
101. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S, Kreuger C, Nitsch R, Meisel A, and Weber JR. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 190: 28-33, 2007. (Pubitemid 47625604)
102. Lemaitre B, Nicolas E, Michaut L, Reichhard JM, and Hoffmann JA. The dorsoventral regulatory gene cassetts spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86: 973-983, 1996. (Pubitemid 26336801)
103. Levine B, Kalman J, Mayer L, Fillit HM, and Packer. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241, 1990. (Pubitemid 20225044)
104. Li C, Browder W, and Kao RL. Early activation of transcription factor NF-kB during ischemia in perfused rat heart. Am J Physiol 276: H543-H552, 1999. (Pubitemid 29100623)
105. Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, Browder W, and Williams DL. Modulating Toll-like receptor mediated signaling by (1/3)-b-D-glucan rapidly induces cardioprotection. Cardiovasc Res 61: 538-547, 2003.
106. Li C, Ha T, Liu L, Browder W, and Kao RL. Adenosine prevents activation of transcription factor NF-kappa B and enhances activator protein-1 binding activity in ischemic rat heart. Surgery 127: 161-169, 2000. (Pubitemid 30091262)
107. Li C, Hu Y, Ha T, Kalbfleisch J, Kelley J, Kao R, and Williams D. Scavenger receptor-A (SR-A) plays a critical role in mediating the pathophysiology of myocardial ischemia/reperfusion injury. Shock 31: 10-11, 2009.
108. Li C, Kao RL, Ha T, Kelley J, Browder IW, and Williams DL. Early activation of IKKb during in vivo myocardial ischemia. Am J Physiol Heart Circ Physiol 280: H1264-H1271, 2001.
109. Limmon GV, Arredouani M, McCann KL, Minor RAC, Kobzik L, and Imani F. Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA. FASEB J 22: 159-167, 2008.
110. Linde A, Mosier D, Blecha F, and Melgarejo T. Innate immunity and inflammation-New frontiers in comparative cardiovascular pathology. Cardiovasc Res 73: 26-36, 2006. (Pubitemid 44937178)
111. Lombardo E, DelaRosa O, Mancheno-Corvo P, Menta R, Ramirez C, and Buscher D. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A 15: 1579-1589, 2009.
112. Lu C, Hua F, Liu L, Ha T, Kalbfleisch J, Schweitzer J, Kelley J, Kao R, Williams D, and Li C. Scavenger receptor class-A has a central role in cerebral ischemia/reperfusion injury. J Cereb Blood Flow Metab 30: 1972-1981, 2010.
113. Maekawa Y, Mizue N, Chan A, Shi Y, Liu Y, Dawood S, Chen M, Dawood F, de Couto G, Li GH, Suzuki N, Yeh WC, Gramolini A, Medin JA, and Liu PP. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation 120: 1401-1414, 2009.
114. Mann DL. Stress activated cytokines and the hearts. Cytokine Growth Factor Rev 7: 341-354, 1996.
115. Marmiroli S, Bavelloni A, Faenza I, Sirri A, Ognibene A, Cenni V, Tsukada J, Koyama Y, Ruzzene M, Ferri A, Auron PE, Toker A, and Maraldi NM. Phosphatidylinositol 3-kinase is recruited to a specific site in the activated IL-1 receptor I. FEBS Lett 438: 49-54, 1998. (Pubitemid 28517833)
116. Martin M, Rehani K, Jope RS, and Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6: 777-784, 2005. (Pubitemid 43090463)
117. Matsui T, Ling L, del Monte F, Fukui Y, Franke TF, Hajjar RJ, and Rosenzweig A. Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100: 2373-2379, 1999.
118. MatsumoriA, Yamada T, SuzukiH,MatobaY, and Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72: 561-566, 1994.
119. Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, Nagai S, Koyasu S, Matsumoto K, Takeda K, and Ichijo H. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 6: 587-592, 2005. (Pubitemid 41710729)
120. McDonough KH and Causey KM. Effects of sepsis on recovery of the heart from 50 min ischemia. Shock 1: 432-437, 1994.
121. McMurray J, Abdullah I, Dargie HJ, and Shapiro D. Increased concentrations of tumor necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 66: 356-358, 1991.
122. Medzhitov R and Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev 173: 89-97, 2000. (Pubitemid 30095213)
123. Medzhitov R and Janeway C Jr. Innate Immunity. N Eng J Med 343: 338-344, 2000.
124. Medzhitov R, Preston-Hurlburt P, and Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 1997. (Pubitemid 27334820)
125. Mersmann J, Berkels R, Zacharowski P, Tran N, Koch A, Lekushi K, Dimmeler S, Granja TF, Boehm O, Claycomb WC, and Zacharowski K. Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med 38: 903-909, 2010.
126. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, and Ogihara T. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 3: 894-899, 1997. (Pubitemid 27353450)
127. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 26: 469-476, 2005. (Pubitemid 41139256)
128. Mukhopadhyay S and Gordon S. The role of scavenger receptors in pathogen recognition and innate immunity. Immunobiology 209: 39-49, 2004. (Pubitemid 39255690)
129. Nemoto S, Vallejo JG, Kneufermann P, Misra A, Defreitas G, Carabello BA, andMann DL. Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol 282: H2316-H2323, 2002. (Pubitemid 34663043)
130. Nose PS. Cytokines and reperfusion injury. J Card Surg 8: 305-308, 1993. (Pubitemid 23108469)
131. O'Connell RM, Taganov KD, Boldin MP, Cheng G, and Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104: 1604-1609, 2007. (Pubitemid 46214637)
132. Ojaniemi M, Glumoff V, Harju K, Liljeroos M, Vuori K, and Hallman M. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol 33: 597-605, 2003. (Pubitemid 36367663)
133. Ono K, Matsumori A, Shioi T, Furukawa Y, and Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts-possible implication in left ventricular remodeling. Circulation 98: 148-156, 1998.
134. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Koppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, Waller M, Wick W, and Platten M. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3- dioxygenase-1 via interferonbeta and protein kinase R. Stem Cells 27: 909-919, 2009.
135. Oral H, Kapadia S, Nakano M, Torre-Amione G, Lee J, Lee-Jackson D, Young JB, and Mann DL. Tumor necrosis factor-alpha and the failing human heart. Clin Cardiol 18: IV20-IV27, 1995.
136. Oyama J, Blais C Jr., Liu X, Pu M, Kobzik L, Kelly RA, and Bourcier T. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109: 784-789, 2004. (Pubitemid 38222900)
137. Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A, De Cesaris P, Ziparo E, Del Bufalo D, Sitkovsky MV, Filippini A, and Riccioli A. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia 12: 539-549, 2010.
138. Park HS, Jung HY, Park EY, Kim J, Lee WJ, and Bae YS. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharideinduced production of reactive oxygen species and activation of NF-kappa B. J Immunol 173: 3589-3593, 2004. (Pubitemid 39280716)
139. Parrillo JE. Pathogenetic mechanism of septic shock. N Engl J Med 328: 1471-1477, 1993.
140. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, and Schuette A. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 76: 1539-1553, 1985. (Pubitemid 16193573)
141. Paul D, Samuel SM, and Mualik N. Mesenchymal stem cell: present challengers and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid Redox Signal 11: 1841-1855, 2009.
142. Pinhal-Enfield G, Ramanathan M, Hasko G, Vogel SN, Salzman AL, Boons GJ, and Leibovich SJ. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am J Pathol 163: 711-721, 2003. (Pubitemid 36909432)
143. Platt N and Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional?-The mouse's tale. J Clin Invest 108: 649-654, 2001. (Pubitemid 32906190)
144. Ren XP, Wu J, Wang X, Sartor MA, Qian J, Jones K, Nicolaou P, Pritchard TJ, and Fan GC. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 119: 2357-2366, 2009.
145. Riad A, Jager S, Sobirey M, Escher F, Yaulema-Riss A, Westermann D, Karatas A, Heimesaat MM, Bereswill S, Dragun D, Pauschinger M, Schultheiss HP, and Tschope C. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol 180: 6954-6961, 2008.
146. Rissanen TT and Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 15: 1233-1247, 2007. (Pubitemid 46965318)
147. Rock FL, Hardiman G, Timans JC, Kastelein RA, and Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 95: 588-593, 1998. (Pubitemid 28083787)
148. Rowland RT, Cleveland JC, Meng X, Ao L, Harken AH, and Brown JM. A single endotoxin challenge induces delayed myocardial protection against infarction. J Surg Res 63: 193-198, 1996. (Pubitemid 26197194)
149. Ruse M and Knaus UG. New players in TLR-mediated innate immunity: PI3K and small Rho GTPases. Immunol Res 34: 33-48, 2006. (Pubitemid 43780375)
150. Sakata Y, Dong J-W, Vallejo JG, Huang C-H, Baker JS, Tracey KJ, Tacheuchi O, Akira S, and Mann DL. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 292: H503-H509, 2007. (Pubitemid 46105213)
151. Samuel SM, Akita Y, Paul D, Thirunavukkarasu M, Zhan L, Sudhakaran PR, Li C, and Maulik N. Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats. Diabetes 59: 51-60, 2010.
152. Sarkar SN, Peters KL, Elso CP, Sakamoto S, Pal S, and Sen GC. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat Struct Mol Biol 11: 1060-1067, 2004. (Pubitemid 39453334)
153. Sawa Y, Morishita R, Suzuki K, Kagisaki K, Kaneda Y, Maeda K, Kadoba K, and Matsuda H. A novel strategy for myocardial protection using in vivo transfection of cis element "decoy" against NFkB binding site. Evidence for a role of NFkB in ischemia-reperfusion injury. Circulation 96: II-280-II-285, 1997.
154. Schroen B and Heymans S. MicroRNAs and beyond: the heart reveals its treasures. Hypertension 54: 1189-1194, 2009.
155. Seimon TA, Obstfeld A, Moore KJ, Golenbock DT, and Tabas I. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. PNAS 103: 19794-19799, 2006. (Pubitemid 46037510)
156. Seta Y, Shan K, Bozkurt B, Oral H, and Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2: 243-249, 1996.
157. Sheedy FJ and O'Neill LAJ. Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Ann Rheum Dis 67: iii50-iii55, 2008.
158. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ, Pohlman TH, Shimpo H, and Verrier ED. Inhibition of toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 114: I-270-I-274, 2006. (Pubitemid 44297162)
159. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, Takeuchi O, Akira S, Takeishi Y, and Kubota I. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108: 2905-2910, 2003. (Pubitemid 37517819)
160. Sierra SS, Deshmukh SD, Kalnitski J, Kuenzi P, Wymann MP, Golenbock DT, and Henneke P. Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. EMBO J 28: 2018-2027, 2009.
161. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, and Moore KJ. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11: 155-161, 2009.
162. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, and Rasmussen HS. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEDF121) versus maximum medical treatment. Gene Ther 13: 1503-1511, 2006. (Pubitemid 44574158)
163. Taganov KD, Boldin MP, and Baltimore D. MicroRNAs and immunity: tiny players in a big field. Immunity 26: 133-137, 2007. (Pubitemid 46329443)
164. Taganov KD, Boldin MP, Chang K-J, and Baltimore D. NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. PHAS 103: 12481-12486, 2006. (Pubitemid 44267285)
165. Takeishi Y and Kubota I. Role of Toll-like receptor mediated signaling pathway in ischemic heart. Front Biosci 14: 2553-2558, 2009.
166. Takeuchi O and Akira S. Pattern recognition receptors and inflammation. Cell 140: 805-820, 2010.
167. Tavener SA, Long EM, Robbins SM, McRae KM, Remmen HV, and Kubes P. Immune cell toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 95: 700-707, 2004. (Pubitemid 39331930)
168. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, and Croce CM. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179: 5082-5089, 2007.
169. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pasterkamp G, and de Kleijn DP. Tolllike receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 102: 257-264, 2008. (Pubitemid 351674064)
170. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, and Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26: 99-107, 2008.
171. Tomic S, Djokic J, Vasilijic S, Vucevic D, Todorovic V, Supic G, and Colic M. Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists. Stem Cells Dev 2010 [Epub ahead of print]; DOI: 10.1089/scd.2010.0145.
172. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, and Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93: 704-711, 1996.
173. Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, and Triantafilou K. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem 281: 31002-31011, 2006. (Pubitemid 44582155)
174. van Duin D, Medzhitov R, and Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 27: 49-55, 2006. (Pubitemid 43083564)
175. van Rooij E, Marshall WS, and Olson EN. Toward micro-RNA-based therapeutics for heart disease: the sense in antisense. Circ Res 103: 919-928, 2008.
176. Varoga D, Paulsen F, Mentlein R, Fay J, Kurz B, Schutz R, Wruck C, Goldring MB, and Pufe T. TLR-2-mediated induction of vascular endothelial growth factor (VDGF) in cartilage in septic joint disease. J Pathol 210: 315-324, 2006. (Pubitemid 44660510)
177. Wang YP, Sato C, Mizoguchi K, Yamashita Y, Oe M, and Maeta H. Lipopolysaccharide triggers late preconditioning against myocardial infarction via inducible nitric oxide synthase. Cardiovasc Res 56: 1-3, 2002.
178. Wang ZJ, Zhang FM, Wang LS, Yao YW, Zhao Q, and Gao X. Lipopolysaccharides can protect mesenchymal stem cells (MSCs) from oxidative stress-induced apoptosis and enhance proliferation of MSCs via Toll-like receptor (TLR)-4 and PI3K/Akt. Cell Biol Int 33: 665-674, 2009.
179. Waterman RS, Tomchuck SL, Henkle SL, and Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE 5: 1-14, 2010.
180. Williams DL, Ozment-Skelton T, and Li C. Modulation of the phosphoinositide-3-kinase signaling pathway alters host resistance to sepsis, inflammation, and ischemia/reperfusion injury. Shock 25: 432-439, 2006.
181. Wollert KC and Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol 7: 204-215, 2010.
182. Wright SD. Toll, a new piece in the puzzle of innate immunity. J Exp Med 189: 605-609, 1999. (Pubitemid 29193360)
183. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z, and Yang B. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 120: 3045-3052, 2007. (Pubitemid 47517087)
184. Xu WY, Wang L, Wang HM, Wang YQ, Liang YF, Zhao TT, and Wu YZ. TLR2 and TLR4 agonists synergistically up-regulate SR-A in RAW264.7 through p38. Mol Immunol 44: 2315-2323, 2007. (Pubitemid 46097120)
185. Yamazaki T, Yoshinori S, Tamatan T, Miyasaka M, Yagita H, Okumura H, Nagai R, and Yazaki Y. Expression of intercellular adhesion molecule-1 in rat heart with ischemia/reperfusion and limitation of infarct size by treatment with antibodies against cell adhesion molecules. Am J Pathol 143: 410-418, 1993. (Pubitemid 24058196)
186. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, and Wang Z. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486-491, 2007. (Pubitemid 46559834)
187. Yao Y, Zhang F, Wang L, Zhang G, Wang Z, Chen J, and Gao X. Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. J Biomed Sci 16: 74-78, 2009.
188. Yao Z, Auchampach JA, Pieper GM, and Gross G. Cardioprotective effects of monophosphoryl lipid-A, a novel endotoxin analogue, in dog. Cardiovasc Res 27: 832-838, 1993. (Pubitemid 23162681)
189. Yao Z, Rasmussen JL, Hirt JL, Mei DA, Pieper GM, and Gross GJ. Effects of monophosphoryl lipid-A on myocardial ischemia/reperfusion in dogs. J Cardiovasc Pharmacol 22: 653-663, 1993. (Pubitemid 23286764)
190. Yi H, Yu X, Gao P, Wang Y, Baek S-H, Chen X, Kim HL, Subjeck JR, and Wang X-Y. Pattern recognition scavenger receptor SRA/CD204 down-regulates Toll-like receptor 4 signaling-dependent CD8 T-cell activation. Blood 113: 5819-5828, 2009.
191. Zacharowski K, Frank S, Otto M, Chatterjee PK, Cuzzocrea S, Hafner G, Pfeilschifter J, and Thiemermann C. Lipoteichoic acid induces delayed protection in the rat heart, a comparison with endotoxin. Arterioscler Thromb Vasc Biol 20: 1521-1528, 2000. (Pubitemid 30353883)
192. Zhang G and Ghosh S. Toll-like receptor-mediated NF-kB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 107: 13-19, 2001. (Pubitemid 32047406)
193. Zhao L, Kirsch CC, Hagen SR, and Elliott GT. Presenvation of global cardiac function in the rabbit following protracted ischemia/reperfusion using monphosphoryl lipid-A (MLA). J Mol Cell Cardiol 28: 197-208, 1996. (Pubitemid 26110465)
194. Zhu FG, Reich CF, and Pisetsky DS. The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides. Immunology 103: 226-234, 2001. (Pubitemid 32521352)
195. Zhu Q, Ha T, Li Y, Kelley J, Browder W, Williams D, and Li C. TLR4 and TLR2 agonists induced cardioprotection through different mechanisms. Exp Biol 2004 Meet Abstr 18: A264, 2004.